Previous 10 | Next 10 |
Unity Biotechnology (NASDAQ: UBX ) -51% on stumble with lead drug . More news on: Unity Biotechnology, Inc., Interpace Biosciences, Inc., Taiwan Liposome Company, Ltd., Stocks on the move, , Read more ...
Unity Biotechnology's (NASDAQ: UBX ) lead candidate UBX0101, a p53/MDM2 interaction inhibitor, failed to sufficiently separate from placebo at week 12 in a Phase 2 clinical trial in patients with moderate-to-severe osteoarthritis of the knee. Specifically, there was no statistically sign...
UBX0101 failed to meet 12-week primary endpoint Guidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near-term UNITY to hold investor and analyst conference call ...
SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercu...
Unity Biotechnology (NASDAQ: UBX ) : Q2 GAAP EPS of -$0.38 beats by $0.13 . More news on: Unity Biotechnology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter end...
SAN FRANCISCO, July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter e...
Unity Biotechnology (NASDAQ: UBX ) finished after-hours trading up 8.3% after an initiation by Roth Capital at Buy. More news on: Unity Biotechnology, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN FRANCISCO, July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter e...
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Bob Goeltz, chief financial officer,...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this n...
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...